Related Experiment Videos
Adjuvant therapy for resectable rectal and colonic cancer
1Department of Colorectal Surgery, St George's Hospital, London, UK.
The British Journal of Surgery
|April 8, 1998
Summary
Adjuvant therapies like preoperative radiotherapy and postoperative chemoradiotherapy improve survival for rectal cancer. Postoperative chemotherapy benefits colon cancer patients, though optimal adjuvant strategies require further research.
Area of Science:
- Oncology
- Surgical Oncology
- Gastrointestinal Oncology
Background:
- Rectal and colonic carcinoma recurrence rates are significant post-surgery.
- Adjuvant therapies are employed to enhance patient prognosis.
- Optimal surgical management alone is insufficient for many cases.
Purpose of the Study:
- To critically review adjuvant therapy's role in resectable rectal and colonic carcinoma.
- To assess evidence for radiotherapy, chemotherapy, and chemoradiotherapy combined with surgery.
- To evaluate emerging treatment modalities in gastrointestinal cancer management.
Main Methods:
- Systematic review of clinical trials and evidence.
- Critical appraisal of adjuvant treatment efficacy.
- Analysis of survival data and recurrence rates.
Main Results:
- Preoperative radiotherapy superior to postoperative for rectal cancer local recurrence reduction.
- Postoperative chemoradiotherapy shows survival benefit for rectal cancer (Dukes C).
- Fluorouracil chemotherapy improves survival for Dukes C colon cancer.
Conclusions:
- Preoperative radiotherapy and postoperative chemoradiotherapy offer survival advantages for rectal cancer.
- Postoperative chemotherapy is beneficial for Dukes C colon cancer.
- Optimal adjuvant therapy combinations and sequencing remain under investigation.